R. Angelo de Claro

2.1k total citations
40 papers, 815 citations indexed

About

R. Angelo de Claro is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, R. Angelo de Claro has authored 40 papers receiving a total of 815 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Hematology, 14 papers in Genetics and 11 papers in Oncology. Recurrent topics in R. Angelo de Claro's work include Acute Myeloid Leukemia Research (11 papers), Chronic Myeloid Leukemia Treatments (11 papers) and Acute Lymphoblastic Leukemia research (9 papers). R. Angelo de Claro is often cited by papers focused on Acute Myeloid Leukemia Research (11 papers), Chronic Myeloid Leukemia Treatments (11 papers) and Acute Lymphoblastic Leukemia research (9 papers). R. Angelo de Claro collaborates with scholars based in United States, Malaysia and France. R. Angelo de Claro's co-authors include Richard Pazdur, Yvette L. Kasamon, Ann T. Farrell, Gideon M. Blumenthal, Yuan Li Shen, Yaping Wang, Bindu George, Amy E. McKee, Jingjing Ye and Shiowjen Lee and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Blood.

In The Last Decade

R. Angelo de Claro

36 papers receiving 801 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
R. Angelo de Claro United States 15 424 202 201 154 113 40 815
Douglas W. Sborov United States 20 602 1.4× 559 2.8× 149 0.7× 591 3.8× 59 0.5× 118 1.2k
Prakash Kharel United States 6 739 1.7× 249 1.2× 342 1.7× 102 0.7× 43 0.4× 13 1.0k
Véronique D’Hondt France 21 781 1.8× 298 1.5× 120 0.6× 163 1.1× 102 0.9× 83 1.3k
Matthew Mei United States 20 523 1.2× 216 1.1× 121 0.6× 286 1.9× 391 3.5× 108 1.1k
Gordon Moody United States 11 303 0.7× 281 1.4× 139 0.7× 135 0.9× 43 0.4× 24 836
Khalid Mezzi United States 12 426 1.0× 411 2.0× 142 0.7× 499 3.2× 39 0.3× 26 788
Shilpen Patel United States 9 989 2.3× 219 1.1× 287 1.4× 60 0.4× 61 0.5× 20 1.3k
Gareth P. Gregory Australia 16 495 1.2× 290 1.4× 144 0.7× 184 1.2× 421 3.7× 74 956
Eri Matsuki Japan 11 249 0.6× 61 0.3× 132 0.7× 153 1.0× 134 1.2× 41 492
Sherilyn A. Tuazon United States 10 494 1.2× 476 2.4× 128 0.6× 517 3.4× 63 0.6× 27 941

Countries citing papers authored by R. Angelo de Claro

Since Specialization
Citations

This map shows the geographic impact of R. Angelo de Claro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Angelo de Claro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Angelo de Claro more than expected).

Fields of papers citing papers by R. Angelo de Claro

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Angelo de Claro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Angelo de Claro. The network helps show where R. Angelo de Claro may publish in the future.

Co-authorship network of co-authors of R. Angelo de Claro

This figure shows the co-authorship network connecting the top 25 collaborators of R. Angelo de Claro. A scholar is included among the top collaborators of R. Angelo de Claro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Angelo de Claro. R. Angelo de Claro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Norsworthy, Kelly J., Donna R. Rivera, Joseph Wynne, et al.. (2025). FDA Approval Summary: Abatacept for the Prophylaxis of Acute GVHD. Clinical Cancer Research. 31(15). 3118–3123.
2.
Woods, Ashley, Dianne Pulte, Jonathon Vallejo, et al.. (2025). FDA Approval Summary: Ivosidenib for Treatment of Adult Patients with Relapsed/Refractory Myelodysplastic Syndrome with an IDH1 Mutation. Clinical Cancer Research. 31(17). 3613–3617. 1 indexed citations
3.
Le, Robert Q., Kamar Godder, Moran Choe, et al.. (2025). FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy. Clinical Cancer Research. 31(17). 3607–3612.
4.
Rabik, Cara A., Shu Wang, Donna Przepiorka, et al.. (2025). FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy. Clinical Cancer Research. 31(20). 4230–4238.
5.
Woods, Ashley, Kelly J. Norsworthy, Moran Choe, et al.. (2024). FDA Approval Summary: Olutasidenib for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase 1 Mutation. Clinical Cancer Research. 31(1). 12–17. 1 indexed citations
6.
Cortes, Jörge E., Elisabetta Abruzzese, Elyce Cardonick, et al.. (2024). Perspectives on Drug Development for the Treatment of Chronic Myeloid Leukemia in Pregnant Patients and Patients Who Are Breastfeeding. Clinical Cancer Research. 30(17). 3658–3666. 2 indexed citations
7.
Hunter, Anthony M., Mrinal M. Patnaik, Raphaël Itzykson, et al.. (2024). Perspectives on drug development in chronic myelomonocytic leukemia: changing the paradigm. Blood. 144(19). 1987–1992. 4 indexed citations
8.
Chow, Edwin C.Y., Alexei Ionan, Shwu‐Luan Lee, et al.. (2024). FDA Approval Summary: Asciminib for Ph+ CML in Chronic Phase Treated with Two or More Tyrosine Kinase Inhibitors and for the T315I Mutation. Clinical Cancer Research. 30(19). 4266–4271. 2 indexed citations
9.
Howlader, Nadia, Elad Sharon, Lori A. Ehrlich, et al.. (2023). The Impact of Improved Treatments on Survival of Adult U.S. Leukemia Patients: 1990–2018. Cancer Epidemiology Biomarkers & Prevention. 32(6). 744–747. 5 indexed citations
10.
Woods, Ashley, Kelly J. Norsworthy, Jonathon Vallejo, et al.. (2023). FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation. Clinical Cancer Research. 30(7). 1226–1231. 16 indexed citations
11.
Sekeres, Mikkael A., Nina Kim, Amy E. DeZern, et al.. (2023). Considerations for Drug Development in Myelodysplastic Syndromes. Clinical Cancer Research. 29(14). 2573–2579. 3 indexed citations
12.
Jen, Emily Y., Xin Wang, Meng Li, et al.. (2022). FDA Approval Summary: Oral Azacitidine for Continued Treatment of Adults with Acute Myeloid Leukemia Unable to Complete Intensive Curative Therapy. Clinical Cancer Research. 28(14). 2989–2993. 14 indexed citations
13.
Sweet, Kendra, Jörge E. Cortes, Jane F. Apperley, et al.. (2022). Project Confirm: Accelerated Drug Approvals for Chronic Myeloid Leukemia. Clinical Cancer Research. 29(12). 2179–2183. 1 indexed citations
14.
Agrawal, Sundeep, Shaily Arora, Laleh Amiri‐Kordestani, et al.. (2022). Use of Single-Arm Trials for US Food and Drug Administration Drug Approval in Oncology, 2002-2021. JAMA Oncology. 9(2). 266–266. 43 indexed citations
15.
Pulte, Dianne, Kelly J. Norsworthy, Yaping Wang, et al.. (2021). FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation. Clinical Cancer Research. 27(13). 3515–3521. 57 indexed citations
16.
Rivera, Donna R., Jennifer J. Lee, Melanie Royce, et al.. (2021). FDA Oncology Center of Excellence Review of Real World Data Submissions Supporting Drug Development in Hematologic Malignancies. Blood. 138(Supplement 1). 5037–5037. 2 indexed citations
17.
Claro, R. Angelo de, Jennifer Gao, Tamy Kim, et al.. (2020). U.S. Food and Drug Administration: Initial Experience with the Real-Time Oncology Review Program. Clinical Cancer Research. 27(1). 11–14. 12 indexed citations
18.
Ye, Jingjing, Gregory H. Reaman, R. Angelo de Claro, & Rajeshwari Sridhara. (2020). A Bayesian approach in design and analysis of pediatric cancer clinical trials. Pharmaceutical Statistics. 19(6). 814–826. 19 indexed citations
19.
Kasamon, Yvette L., Haiyan Chen, R. Angelo de Claro, et al.. (2019). FDA Approval Summary: Mogamulizumab-kpkc for Mycosis Fungoides and Sézary Syndrome. Clinical Cancer Research. 25(24). 7275–7280. 51 indexed citations
20.
Claro, R. Angelo de, Xiaodong Zhu, Jingjing Tang, et al.. (2011). Hematopoietic Fas Deficiency Does Not Affect Experimental Atherosclerotic Lesion Formation despite Inducing a Proatherogenic State. American Journal Of Pathology. 178(6). 2931–2937. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Douglas W. Sborov Breakdown of academic impact, for papers by Prakash Kharel Breakdown of academic impact, for papers by Véronique D’Hondt Breakdown of academic impact, for papers by Matthew Mei Breakdown of academic impact, for papers by Gordon Moody Breakdown of academic impact, for papers by Khalid Mezzi Breakdown of academic impact, for papers by Shilpen Patel Breakdown of academic impact, for papers by Gareth P. Gregory Breakdown of academic impact, for papers by Eri Matsuki Breakdown of academic impact, for papers by Sherilyn A. Tuazon
Rankless by CCL
2026